Progeria
Hutchinson-Gilford progeria syndrome is a rare genetic disease in which children age dramatically fast and usually die of heart and blood-vessel disease in adolescence. It is one of the clearest natural experiments in aging biology, and it is the rare case with an approved drug, lonafarnib. That drug was approved on small trials with no placebo group, and it slows the disease rather than curing it.
Lonafarnib is a treatment for a rare childhood disease, not an anti-aging drug, and it does not generalise to healthy adults.
What goes wrong
In Hutchinson-Gilford progeria syndrome (HGPS), a mutation produces a malformed version of lamin, a structural protein that lines the inside of the cell nucleus and helps protect the DNA. The faulty lamin deforms the nucleus and destabilises the genome. Children with HGPS age dramatically fast and characteristically die of cardiovascular disease in adolescence.[1]
That is why the disease matters beyond the families it affects. Together with a group of inherited DNA-repair disorders, it shows that when the machinery that maintains the genome breaks badly, aging speeds up. The wider argument is on genomic instability.
Lonafarnib: the first approved treatment
The defective lamin needs a chemical tag, added by a process called farnesylation, to do its damage. Lonafarnib blocks farnesylation, and it became the first treatment ever approved for a progeria.[2]
How strong the evidence is
The evidence comes from small single-group trials with no placebo or untreated comparison group.
- Arteries. In the first trial, 25 children took lonafarnib for at least two years, and arterial stiffness improved in some of them. The authors called this preliminary evidence.[3]
- Survival. The survival benefit comes from comparing treated children with matched untreated children from a separate natural-history study. After a median 2.2 years of treatment, 1 of 27 treated children had died (3.7%), against 9 of 27 untreated children (33.3%). That is a hazard ratio of 0.12, or roughly 88% lower risk of death. With so few deaths, though, the 95% confidence interval (the range where the true effect plausibly lies) ran all the way from 0.01 to 0.93. The authors note that this observational design limits interpretation.[4]
- Average gain. An earlier matched analysis of children treated with farnesylation inhibitors put the gain in average survival at about 1.6 years.[5]
So the results point the same way, but the size of the survival gain is uncertain. The drug slows the disease. It does not cure it.
What comes next
A second drug aimed at the faulty lamin, progerinin, has finished a small dose-finding trial in 10 people with HGPS. Its results have not yet been posted.[6]
What it means for everyone else
- It is evidence about aging, not a treatment for it. Progeria shows that a badly broken genome-maintenance system speeds aging up. Whether ordinary, everyday wear on the genome sets the pace of normal aging is a separate and less settled question, covered on genomic instability.
- No one should take lonafarnib to slow normal aging. It is approved only for progeria, it is not established for healthy adults, and its benefit in progeria does not generalise to them.
Further reading
- Gordon LB, et al. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA 2018.[7]
- Gordon LB, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 2012.[8]
- Gordon LB, et al. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation 2014.[9]
- Siametis A, et al. From genome to geroscience: how DNA damage shapes systemic decline. Bioessays 2025.[10]